Impact of the adherence to medical treatment on the main urinary metabolic disorders in patients with kidney stones by Manzo, Braulio Omar et al.
Asian Journal of Urology (2021) 8, 275e279Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate/ajurOriginal ArticleImpact of the adherence to medical
treatment on the main urinary metabolic
disorders in patients with kidney stones
Braulio Omar Manzo a,*, Jose David Cabrera a,
Esteban Emiliani b, Hector Manuel Sánchez a,
Brian Howard Eisner c, Jose Ernesto Torres aa Urology Department, Hospital Regional de Alta Especialidad del Bajı́o, Blvd. Milenio #130, Col. San
Carlos la Roncha, León, Guanajuato, Mexico
b Urology Department, Fundación Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain
c Urology Department, Massachusetts General Hospital, Harvard Medical School, Boston, USAReceived 9 November 2019; received in revised form 6 January 2020; accepted 1 June 2020









Peer review under responsibility o
https://doi.org/10.1016/j.ajur.2020.0
2214-3882/ª 2021 Editorial Office of A
the CC BY-NC-ND license (http://creaAbstract Objective: To assess the effect of the adherence to medical treatment on urinary
parameters in the 24-h metabolic study of patients with kidney stones.
Methods: A retrospective, longitudinal, descriptive, and observational study was carried out
by reviewing the hospital electronic medical record from 2014 to 2018. The adherence to drug
treatment was measured 6 months after its initiation, and the numerical values of the meta-
bolic studies were compared. Wilcoxon tests were performed to compare the difference
before and after treatment.
Results: Ninety patients were evaluated, with 73.3% of adherence. The 180-day overall adher-
ence rate was 61.2% in patients treated with a single drug and 85.4% in patients treated with
multiple drugs. There is a statistically significant increase in citrate levels in patients with good
adherence in comparison with non-adherent patients (pZ0.031 vs. pZ0.528).
Conclusions: Medical treatment and dietary measures in patients with kidney stones have an
initial impact at 6 months on the values of the main urinary metabolic alterations that predis-
pose to calculi formation; the most significant is seen in those patients with adherence to med-
ical treatment for hypocitraturia.
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The recurrence rate of renal stones is about 50% at 5-year
follow-up if pharmacologic treatment is not given [1e3].
The most critical factors that contribute to calcium stones
formation are hypercalciuria, hypocitraturia, hyper-
uricosuria, and hyperoxaluria [4,5]. Nowadays, the 24-hour
urine collection is the gold standard method to identify
such abnormalities to guide the pharmacological treatment
and dietary modifications [6].
Adherence to an established treatment is defined as the
extent to which patients take medications prescribed by
their health care providers. Also, adherence is a corner-
stone for an adequate response and resolution of any
human disease like all metabolic disorders responsible for
kidney stones [7e10]. Additionally, adherence is a crucial
gauge of health care quality, and nonadherence is associ-
ated with poor health outcomes and substantial economic
costs [11]. Despite the above, nonadherence to drug ther-
apy is one of the main limitations in the treatment of
chronic diseases, reducing the benefits that could be ob-
tained [12]. Efforts to accurately measure and improve
adherence have received increasing attention from pa-
tients, physicians, payers, and all the rest of healthcare
stakeholders.
Unfortunately, today there is no consensual standard for
what adequate adherence constitutes and how to measure
it adequately. A 50% adherence rate has been described for
chronic illness such as hypertension and type 2 diabetes in a
6-month follow-up [13]. Prior studies on this topic have
reported a 70% compliance rate for stone patients followed
explicitly in a comprehensive kidney stone center. It is
likely that compliance for the typical patient, in a non-
specialized center, is significantly lower [14]. Therefore,
the purpose of the current study was to describe the pa-
tients’ compliance rates to the stone prevention regimens
and to evaluate its influence in the 24-hour urine parame-
ters at 6 months of follow-up.
2. Methods
A retrospective cohort study was conducted, with a longi-
tudinal, descriptive, and observational design approved by
the ethics committee with the registration number (CI/
HRAEB/2019/040). From 2014 to 2018, we analyzed all
adult patients with kidney stones diagnosis and stone-free
state after their surgical procedure. All patients had two
metabolic studies, including 24-hour urine panel and uri-
nary pH determination in single sample separately with
dipstick (Chemstrip by Roche Diagnostics, Indianapolis,
USA), and a reflectance photometer (Urisys 1100, Di-
agnostics, Laval QC): The first one performed at the time of
determining stone-free status and the second in the follow-
up after medical intervention at 6 months. Medical treat-
ment was directed depending on the patient’s metabolic
abnormality in the first metabolic evaluation. We defined
hypocitraturia as urine citrate of <320 mg/day, hyper-
oxaluria as a urine oxalate of >0.4 mmol/day, hyper-
calciuria >200 mg/day and hyperuricosuria as a urine uric
acid of >0.7 g/day. All patients received a printed sheet
with the dietary recommendations corresponding to eachmetabolic alteration. Standardized treatment regimens
were as follows: For hypocitraturia were given potassium
citrate (KCit) 2 g PO BID bid; for hypercalciuria were given
hydrochlorothiazide (HCT) 25 mg PO QD; for hyper-
uricosuria were given allopurinol (Allo) 300 mg PO QD, and
finally, hyperoxaluria was managed with low oxalate/
calcium-rich diet [15]. For patients with two or more al-
terations of 24-hour urine composition, they received
multiple treatments with two or more prescriptions, as well
as combined dietary modifications (Supplementary mate-
rial). Compliance or adherence to dietary modifications was
evaluated by self-reported dietary compliance as described
by previous authors [16,17].
2.1. Determination of adherence
Adherence to drug treatment was determined by reviewing
the electronic medical record. To estimate adherence, we
use the formula for the proportion of days covered (PDC)
described by Dauw et al. [18]. The PDC is calculated as the
number of days covered by a specific drug divided by the
total number of days in the follow-up period. For patients
taking more than one medication, we estimated the
adherence by calculating the average class-specific PDC
values. We used a follow-up period of 180 days after the
first drug prescription in our study, and then we multiplied
the PDC by 100 to express it as a percentage. According to
previous studies, we defined a good adherence if this per-
centage was equal or greater than 80%. Patients with less
than 80% and those who lost the prescription or had irreg-
ular follow-up were considered as having poor adherence.
2.2. Statistical analysis
The program used for statistical purposes was IBM SPSS
version 25 (IBM Corp., Armonk, NY). A univariate analysis
was carried out using frequencies and percentages for
categorical data and measures of central tendency and
corresponding dispersion according to the distribution of
the data in the quantitative variables, following the
Kolmogorov-Smirnov normality test. Wilcoxon tests were
performed to compare the difference before and after
medical treatment. A p<0.05 and a 95% bilateral confi-
dence interval were considered statistically significant.
3. Results
Ninety patients met inclusion criteria (i.e., stone-free sta-
tus after surgery and at least 180 days of follow-up for
metabolic stone evaluation and treatment). The de-
mographic data of the 90 patients are presented in Table 1.
The relative prevalence of the 24-hour urine abnormalities,
taking into account that many patients had more than one
disorder, was as follows: Hypocitraturia (41.26%), hyper-
uricosuria (14.28%), hypercalciuria (16.40%) and hyper-
oxaluria (28.04%) (see Table 1).
Of the 90 patients included in this study, 36 (40%) were
treated with monotherapy (single drug); the most frequent
treatment was KCit (nZ29), followed by HCT (nZ7) and no
single patient had monotherapy treatment with allopurinol.
Forty-one (45.5%) patients were treated with multi-drug
Table 1 Baseline and demographic characteristics.




Age (year) 45.4 (13.2)a
DM2, n 8 8.9
HTN, n 25 27.8
BMI (kg/m2) 28.8 (4.3)a
Normal, n 17 18.9
Overweight, n 42 46.7
Grade I Obesity, n 30 33.3
Grade II Obesity, n 1 1.1
Stone volume (mm2) 252 (124e447.3)b








DM2, Type II Diabetes; HTN, hypertension; BMI, body mass index.
a Mean (Standard Deviation).
b Median (Quartile).
The impact of adherence to medical treatment 277therapy. The most frequent combination was KCitþHCT
(nZ12), KCitþAllo (nZ9), KCitþHCTþAllo (nZ8),
HCTþAllo (nZ6), KCitþMg (nZ3), CitþCalcitriol (nZ3).
Thirteen (14.4%) patients with hyperoxaluria were managed
just with dietary therapy. The 180-day overall adherence
rate was 73.3% (61.2% in patients treated with a single drug
and 85.4% in patients treated with multiple drugs). The
overall differences in the urine parameters of patients after
pharmacologic treatment are seen in Table 2.
Patients were sub-stratified by medication therapy and
divided into good and poor adherence to medical treatment
(Tables 3 and 4). When comparing patients who wereTable 2 Differences between the first metabolic study and its
Metabolic disorder Before, mean (range)
Hypocitraturia (nZ78)
Urinary pH 6 (5e7)
24 h urine Cit (mg/d) 62 (20.5e208)
24 h volume (mL) 1900 (1485e2585)
Hyperuricosuria (nZ27)
Urinary pH 6 (5.5e6.7)
24 h urine UA (g/d) 0.8 (0.5e10)
24 h volume (mL) 2100 (1780e2800)
Hypercalciuria (nZ31)
Urinary pH 6 (5.3e6.5)
24 h urine Ca (mg/d) 302.4 (172.2e367.4)
24 h volume (mL) 2200 (1720e2970)
Hyperoxaluria (nZ53)
24 h urine Ox (mmol/d) 0.6 (0.5e0.8)
24 h volume (mL) 2390 (1845e2950)
*Statistically significant. Wilcoxon tests were performed to compare th
95% bilateral confidence interval were considered statistically significadherent versus those who were not, a statistical difference
was seen in potassium citrate-adherent patients showing a
significant increase (Table 3) in the urine citrate (from
60 mg/day to 141.5 mg/day) (pZ0.031). Non-adherent pa-
tients (Table 4) failed to demonstrate such an increase in the
urine citrate (130 mg/day to 248.5 mg/day) (pZ0.5).
For patients with hyperuricosuria, there was a decrease
of 25% in uric acid levels. In those patients with hyper-
calciuria, there was a decrease of 12% in calcium levels.
Finally, in those patients with hyperoxaluria, there were no
changes in the urine oxalate levels. However, neither
adherent nor non-adherent patients demonstrated a sta-
tistically significant difference in urinary parameters at six-
month follow-up (pZnon significant for all). These results
are shown in Tables 3 and 4.4. Discussion
Adherence to medical treatment is a complicated issue to
evaluate. Some strategies to evaluate this include
surveying the patients, directly observing medication tak-
ing, measuring drug or metabolites in plasma/urine, or
using electronic medication monitors. Previous studies
evaluating compliance used the self-reporting patients
(directly surveying the patients) being the simplest to
achieve and considered to be reliable in the published
literature [11,12]. Similar to Dauw et al. [18], we evaluated
patient’s adherence to the proportion of days formula in
order to evaluate the impact of the adherence to medical
treatment and dietary modifications on the primary meta-
bolic disorders that predispose to stone formation in pa-
tients diagnosed with kidney stones.
Reducing recurrence is the main objective of preventive
treatment, and it should be individualized concerning the
specific metabolic alteration of each patient. Thiazides are
the standard management for idiopathic hypercalciuria;
compared to placebo, a significant decrease in stone
recurrence (more than 60% of reduction) has been docu-
mented [15]. Hypocitraturia is treated by alkalicontrol 6 months after the start of medical treatment.












e difference before and after medical treatment. A p<0.05 and a
ant.
Table 3 Changes showed in the 24-hour urine parameters in patients with adherence to medical and dietary treatment.
Metabolic alteration Variable Before, mean (range) After, mean (range) p-Value
Hypocitraturia (nZ78) 24 h Cit (mg/d) 60 (18e191.5) 141.5 (29.2e274) 0.031*
Hyperuricosuria (nZ27) 24 h UA (g/d) 0.8 (0.4e22.6) 0.6 (0.4e0.9) 0.088
Hypercalciuria (nZ31) 24 h Ca (mg/d) 297.5 (167.7e366.9) 261.8 (191.7e342.0) 0.889
Hyperoxaluria (nZ53) 24 h Ox (mmol/d) 0.6 (0.5e0.8) 0.6 (0.4e0.7) 0.286
*Statistically significant. Wilcoxon tests were performed to compare the difference before and after medical treatment. A p<0.05 and a
95% bilateral confidence interval were considered statistically significant.
278 B.O. Manzo et al.preparations based on citrate and has been shown to
maintain stone-free rates of 92% in surveillance vs. 58% in
placebo patients [19]. Allopurinol has been indicated for
the treatment of calcium oxalate stones associated with
hyperuricosuria; its use has shown up to a 50% decrease in
the recurrence of lithiasis vs. placebo [20]. In hyper-
oxaluria, the reduction of dietary oxalate is essential; only
52% of patients have adequate compliance with dietary
measures and fluid consumption, achieving a significant
decrease in urinary oxalate levels [16,21,22].
In the current study, we found that adherence to pre-
scribed measures described above resulted in significant
differences in 24-hour urine composition only in patients
taking potassium citrate. At first glance, this is somewhat
surprising, considering that hypercalciuric patients received
a thiazide diuretic and hyperuricosuric patients received
allopurinol. We feel that the best possible explanation for
these findings is likely the diet that is typical of the region in
Mexico where our patients come. This diet is a diet rich in
sodium and animal protein. Sodium is known to reduce or
block the hypocalciuric effects of thiazide diuretics, and a
diet rich in animal protein may result in increased urinary
uric acid excretion and reduce the uric acid lowering effects
of allopurinol. On the other hand, these dietary tendencies
would not be expected to reduce the effects of potassium
citrate, which works by causing systemic alkalization,
inducing citrate excretion into the urine. Another finding to
assess was that urinary pH did not change significantly after
potassium citrate treatment, as is commonly expected. We
use the urine dipstick (Urisys by Roche) as the pH deter-
mination evaluation method, and it has been described that
this kind of study (photometry readers) has considerable
inaccuracy that could cause bias in our results [23].
In our study, 73.3% (61.2% in single drug and 85.4% with
multiple drugs) of patients showed adherence to medical
treatment and dietary recommendations. This adherence
rate is a high percentage compared to the reported in
previous studies. One possible explanation for the high
adherence of our population is that the majority of patients
treated in our center (a tertiary referral center for complexTable 4 Changes showed in the 24-hour urine parameters in pa
Metabolic alteration Variable Before
Hypocitraturia (nZ78) 24 h Cit (mg/d) 130 (3
Hyperuricosuria (nZ27) 24 h UA (g/d) 0.8 (0
Hypercalciuria (nZ31) 24 h Ca (mg/d) 305.1
Hyperoxaluria (nZ53) 24 h Ox (mmol/d) 0.4 (0stone disease) have experienced recurrent or persistent
complicated urinary stones. Therefore, our patients may be
highly motivated to comply with preventive measures and
treatments that were given. Additionally, opposite to pre-
vious studies, our patients summitted to multiple therapies
for more than one metabolic alteration, showed higher
compliance. A big concern, suffering, and even the loss of
one renal unit could be one reason for this high adherence
in patients with multiple metabolic diagnoses, but this
needs to be further studied. Nonetheless, we observed, as
described above, that adherence to therapy only resulted
in significant changes in patients with hypocitraturia.
These findings may be unique to our patient population.
As described above, there exists level 1 evidence that each
of the three medication therapies: Potassium citrate, thia-
zide diuretics, and allopurinol results in a significant reduc-
tion in recurrent stone events. However, these studies were
all performed in a distinct population (United States) where
dietary habits may be different from those of our patients
[20,24,25]. We feel that our findings have significant impli-
cations for the treatment of patients in Mexico with recur-
rent calcium oxalate stone disease. One could assume if
future studies confirm these findings, that the optimal
medication for stone prevention for patients in this region of
Mexico would be potassium citrate-based therapies.
Our study has several limitations, which are inherent in a
retrospective study, such as the definition of adherence. As
reported in previous studies, it is not possible to assess
accurately if the patient took or not the medication,
despite the records in the file and pharmacy. Previous
studies have been based on self-patient reporting to mea-
sure compliance or adherence to medical treatment and
dietary measures. Also, non-adherent patients could have
taken another dietary or herbal treatments not reported to
doctors that could affect their metabolic profile. The study
was conducted in a third level hospital, with a specialized
lithiasis clinic, in which complex and recurrent cases of
kidney stones are treated so that it could be not repre-
sentative of the general population. Although the follow-up
time of our population could be considered a short timetients with no adherence to medical and dietary treatment.
, mean (range) After, mean (range) p-Value
2e322) 248.5 (80.7e281.5) 0.528
.6e5.9) 0.7 (0.6e4.9) 0.327
(226.1e305.1) 228.7 (213.2e228.7) 0.655
.3e0.7) 0.6 (0.5e0.8) 0.374
The impact of adherence to medical treatment 279follow-up for chronic diseases, all the previous studies
evaluating adherence to medical treatment have reported
just 6 months of follow-up [16e18]. Long-term follow-up is
necessary to document the constancy to adherence in
chronic treatments and to observe changes in the 24-hour
urinary metabolic study and its long-term effect on recur-
rence rate changes, stone re-formation, emergency visits,
and even loss of kidney function.
5. Conclusion
Medical treatment and dietary measures in patients with
kidney stones have an initial impact at 6 months on the
values of the main urinary metabolic alterations that pre-
dispose to calculus formation; the most significant is seen in
those patients with adherence to medical treatment for
hypocitraturia.
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